Skip to content

Clinical study on the effect of Clarenicol oral liquid on the relief of pharyngeal symptoms of novel coronavirus pneumonia (COVID-19) in convalescence, suspected patients and other susceptible populations

Clinical study on the effect of Clarenicol oral liquid on the relief of pharyngeal symptoms of novel coronavirus pneumonia (COVID-19) in convalescence, suspected patients and other susceptible populations

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033745
Enrollment
Unknown
Registered
2020-06-11
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sore throat

Interventions

Case series:Keranliyan oral liquid

Sponsors

Maoming People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. At the time of signing the informed consent, 18= age =65, no limitation on men or women; 2. Patients with respiratory symptoms including pharyngeal discomfort, coVID-19 convalescent patients, suspected patients, epidemiological population or susceptible population with respiratory symptoms such as fever; 3. TCM syndrome differentiation of laryngopharyngeal discomfort in the above population is characterized by dampness-heat accumulation of lung syndrome/wind-heat syndrome/wind-heat invasion of lung syndrome/phlegm-heat obstructing lung syndrome/febril-excess of lung heat and other TCM syndromes; 4. The subjects are informed, voluntarily sign the informed consent, and agree to participate in all visits as required by the study plan.

Exclusion criteria

Exclusion criteria: 1. The investigator decides that it is not in the best interest of the subject to participate in this study, or that there are any circumstances in which the protocol cannot be safely followed; 2. People who are known to have an allergic reaction or allergic constitution to the Keranliyan oral liquid or its components; 3. Have participated in or are participating in other clinical researchers in the past 1 month; 4. Positive pregnancy tests during pregnancy or breastfeeding, or before medication; 5. Other conditions that the researcher considers inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Pharyngeal discomfort symptoms such as sore throat, dry pharyngeal burning, congestion of pharyngeal mucosa relief time and relief rate.;The time required for a new fever, cough, muscle soreness, headache, symptom resolution or relief;

Secondary

MeasureTime frame
Other symptoms such as fever, cough, muscle pain, headache and other relief time, rate of relief;Novel Coronavirus double positive rate;Incidence of COVID - 19;Time and incidence of severe COVID-19;TCM symptom score;Drug use (dosage, duration);General condition; Vital signs (temperature, respiration, heart rate, blood pressure);Laboratory examination and auxiliary examination ;Adverse events/adverse reactions;

Countries

China

Contacts

Public ContactYaocai Li

Maoming People's Hospital

1265114220@qq.com+86 18666818110

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026